Hepatitis A Virus in Lao People's Democratic Republic: Seroprevalence and Risk Factors.


Journal

The American journal of tropical medicine and hygiene
ISSN: 1476-1645
Titre abrégé: Am J Trop Med Hyg
Pays: United States
ID NLM: 0370507

Informations de publication

Date de publication:
07 2020
Historique:
pubmed: 29 4 2020
medline: 2 9 2020
entrez: 29 4 2020
Statut: ppublish

Résumé

Despite several recent reports of outbreaks of hepatitis A, little is known about the disease burden in Lao People's Democratic Republic (PDR). We conducted a cross-sectional age-stratified seroprevalence study of anti-hepatitis A virus (HAV) IgG and risk factors in a rural province (Xiengkhouang) and Vientiane capital in Lao PDR. Overall, 62% of participants were anti-HAV positive in Xiengkhouang Province compared with 45.5% in Vientiane capital. In Xiengkhouang, 23.7% of 5- to 10-year-olds were already seropositive compared with 5% in Vientiane. A dramatic increase in seroprevalence occurred between 15- to 20-year and 21- to 30-year age-groups (35.7-62.4%, Xiengkhouang, and 11.5-69.7%, Vientiane) until essentially all older adults were positive in both locations. The main risk factors for HAV antibodies were age, non-Lao-Tai ethnicity, and food-related risk factors. In conclusion, Lao children seem to be exposed very early to HAV, particularly in rural settings, and exposure continues throughout their lives, mostly without being reported. In the older birth cohorts, the high seroprevalence may largely reflect poor sanitation and exposure during childhood. In Vientiane capital, the lower seroprevalence at young ages may reflect better water sanitation since the late 1990s. A comparison with neighboring Thailand indicates that the impact of improved sanitation in Lao PDR began only two decades later. Further improvements in water sanitation, in particular in the rural districts, and better food hygiene are warranted. Our study also suggests that HAV infections are underreported. Improved reporting would provide guidance for targeted interventions to further reduce HAV infections.

Identifiants

pubmed: 32342836
doi: 10.4269/ajtmh.19-0451
pmc: PMC7356461
pii: tpmd190451
doi:
pii:

Substances chimiques

Antibodies, Viral 0
Immunoglobulin G 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

164-168

Références

Food Environ Virol. 2015 Dec;7(4):316-24
pubmed: 26115693
PLoS Pathog. 2015 Jun 25;11(6):e1004867
pubmed: 26110535
Wkly Epidemiol Rec. 2012 Jul 13;87(28/29):261–76
pubmed: 22905367
PLoS One. 2016 Mar 23;11(3):e0151304
pubmed: 27008531
World J Hepatol. 2012 Mar 27;4(3):68-73
pubmed: 22489258
Int J Infect Dis. 2004 Jul;8(4):201-9
pubmed: 15234323
Vaccine. 2010 Sep 24;28(41):6653-7
pubmed: 20723630
J Korean Med Sci. 2013 Jun;28(6):908-14
pubmed: 23772157
Int J Food Microbiol. 2004 Jan 1;90(1):23-41
pubmed: 14672828
Epidemiol Rev. 2006;28:101-11
pubmed: 16775039
Foodborne Pathog Dis. 2013 Jun;10(6):528-32
pubmed: 23614798
J Viral Hepat. 2008 Oct;15 Suppl 2:43-6
pubmed: 18837833
Vaccine. 2000 Feb 18;18 Suppl 1:S61-4
pubmed: 10683551

Auteurs

Vilaysone Khounvisith (V)

1Lao-Lux Laboratory, Institut Pasteur du Laos, Vientiane, Lao PDR.

Xaipasong Xaiyaphet (X)

2Institut de la Francophonie pour la Medecine Tropicale, Lao PDR.

Phetsavanh Chanthavilay (P)

2Institut de la Francophonie pour la Medecine Tropicale, Lao PDR.

Phonethipsavanh Nouanthong (P)

1Lao-Lux Laboratory, Institut Pasteur du Laos, Vientiane, Lao PDR.

Bounta Vongphachanh (B)

1Lao-Lux Laboratory, Institut Pasteur du Laos, Vientiane, Lao PDR.

Daniel Reinharz (D)

2Institut de la Francophonie pour la Medecine Tropicale, Lao PDR.

Claude P Muller (CP)

1Lao-Lux Laboratory, Institut Pasteur du Laos, Vientiane, Lao PDR.
3Department of Infection and Immunity, Luxembourg Institute of Health, Esch-sur-Alzette, Luxembourg.

Antony P Black (AP)

1Lao-Lux Laboratory, Institut Pasteur du Laos, Vientiane, Lao PDR.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH